FEATURED FUNDS
ICICI Prudential Smallcap Fund Direct Plan-Growt..
5Y Return
17.64 %
Invest Now
FEATURED FUNDS
ICICI Prudential Midcap Direct Plan-Growth
5Y Return
16.55 %
Invest Now
FEATURED FUNDS
ICICI Prudential Large & Mid Cap Fund Direct Pla..
5Y Return
14.08 %
Invest Now
FEATURED FUNDS
ICICI Prudential Asset Allocator Fund (FOF) Dire..
5Y Return
13.63 %
Invest Now
FEATURED FUNDS
ICICI Prudential Credit Risk Fund Direct Plan-Gr..
5Y Return
9.22 %
Invest Now
Business News›News›Newsblogs›Covid Live News Updates: Bharat Biotech releases vaccine phase 3 trials data, Covaxin shown to have efficacy of 77.8%
LIVE BLOG
Economic Times | 03 Jul, 2021 | 08.35AM IST
Covid Live News Updates: Bharat Biotech releases vaccine phase 3 trials data, Covaxin shown to have efficacy of 77.8%
Efficacy analysis demonstrates Covaxin to be 93.4% effective against severe symptomatic COVID19. Efficacy data demonstrates 65.2% protection against the SARS-CoV-2, B.1.617.2 Delta variant: Bharat Biotech
!1 New UpdateClick here for latest updates
Calcutta HC directs Bengal govt to provide security to Suvendu Adhikari
While hearing Adhikari's security case, the High Court observed that Adhikari, a Z-category protectee by the Ministry of Home Affairs is adequately covered by the central security force.
Laxmi Nagar to open
After assurance from traders that COVID-appropriate behaviour will be followed, DDMA, District East, directs that t… https://t.co/RPP3mu6zbc
— ANI (@ANI) 1625278474000Bharat Biotech vaccine effectively neutralises Delta variant
Covaxin was immunogenic and highly efficacious against symptomatic and asymptomatic COVID 19 variant associated disease, particularly against severe disease in adults
- Bharat Biotech
Efficacy in Delta cases
BBV152 conferred 65.2% (95% CI: 33.1, 83.0) protection against the SARS CoV 2 Variant of Concern, B.1.617.2 (Delta).
Efficacy in severe cases
Sixteen cases, one vaccinee and 15 placebo recipients, met the severe symptomatic COVID-19 case definition giving a vaccine efficacy of 93.4%
Covaxin efficacy
COVAXIN® Proven SAFE in India's Largest Efficacy Trial. Final Phase-3 Pre-Print Data Published on… https://t.co/cQvdqX8vrN
— BharatBiotech (@BharatBiotech) 1625256640000BB phase 3 trial data
Bharat Biotech concludes final analysis for Covaxin efficacy as part of phase 3 clinical trials, after evaluation of 130 confirmed cases. Covaxin's efficacy demonstrated at 77.8% against symptomatic COVID19 patients
Tirath resignation: BJP MLAs to meet today
Ending days of speculation about a change of guard in the state, Rawat handed over his resignation letter to Governor Baby Rani Maurya past 11 pm, hours after returning from Delhi where he was summoned by the top BJP leadership on Wednesday.
Thai virus surge prompts concern over ICUs, vaccine supply
Health authorities in Thailand reported over 6,200 new COVID-19 cases on Saturday, setting a record for a third straight day, as concerns mounted over shortages of treatment facilities and vaccine supplies.
Florida condo building deemed unsafe, evacuation ordered
The city of North Miami Beach ordered the evacuation of a condominium building Friday after a review found unsafe conditions about 5 miles (8 kilometers) from the site of last week's deadly collapse in South Florida.
Education Ministry in Sri Lanka plans to open schools in July with less than 100 children
Sri Lanka's Education Minister Professor GL Peiris on Friday said that the Education Ministry is hoping to launch a practical program to open schools with less than 100 children in July following recommendations from the health sector.
Firefighters make progress against California forest fires
Firefighters were making progress Friday against Northern California forest fires that burned several homes and forced thousands to flee communities even as authorities prepared for a hot, crowded Fourth of July weekend that could bring the threat of new blazes.
